2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Watts J, Baer M, Yang J, Prebet T, Lee S, Schiller G, Dinner S, Pigneux A, Montesinos P, Wang E, Seiter K, Wei A, De Botton S, Arnan M, Donnellan W, Schwarer A, Récher C, Jonas B, Ferrell P, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard S, Brevard J, Henrick P, Mohamed H, Cortes J. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet Haematology 2022, 10: e46-e58. PMID: 36370742, DOI: 10.1016/s2352-3026(22)00292-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineFebrile NeutropeniaFemaleHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMyelodysplastic SyndromesThrombocytopeniaConceptsAcute myeloid leukemiaInhibitor of mutant isocitrate dehydrogenase 1Recommended phase 2 doseIDH1-mutated acute myeloid leukemiaPhase 2 doseDose-limiting toxicityCombination therapy groupMyeloid leukemiaCombination therapyMyelodysplastic syndromeClinical activityFebrile neutropeniaMonotherapy groupSmall-molecule inhibitor of mutant isocitrate dehydrogenase 1Eastern Cooperative Oncology Group performance status 0Treatment-emergent adverse eventsHigh-risk myelodysplastic syndromeRefractory acute myeloid leukemiaOpen-label clinical trialTherapy groupDose-escalation cohortsPerformance status 0Phase 1/2 studyTreatment-naive patientsPhase 1/2 trial
2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D, Coutre S, De Lima M, Fathi A, Fiorella M, Foran J, Hall A, Jacoby M, Lancet J, LeBlanc T, Mannis G, Marcucci G, Martin M, Mims A, O'Donnell M, Olin R, Peker D, Perl A, Pollyea D, Pratz K, Prebet T, Ravandi F, Shami P, Stone R, Strickland S, Wieduwilt M, Gregory K, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 721-749. PMID: 31200351, DOI: 10.6004/jnccn.2019.0028.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCytogenetic AnalysisDisease-Free SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA AntigensHumansLeukemia, Myeloid, AcuteMedical OncologyMiddle AgedRemission InductionRisk AssessmentTransplantation, HomologousUnited StatesConceptsAcute myeloid leukemiaNCCN Clinical Practice GuidelinesClinical practice guidelinesMyeloid leukemiaTreatment optionsManagement of acute myeloid leukemiaLow-intensity regimensExpansion of treatment optionsAnnual deaths due to leukemiasPractice guidelinesDeaths due to leukemiaAcute leukemiaTargeted therapyAdult patientsDiagnostic evaluationLeukemiaNCCNOptionsRegimensUnited StatesTherapyWorkupPatientsGuidelines